Sotrovimab News and Research

RSS

Evaluating dual direct-acting antivirals against persistent COVID-19

Researchers assessed the efficiency of dual direct-acting antivirals in treating persistent coronavirus disease 2019 (COVID-19).

7 Nov 2022

Nebulized mRNA-encoded antibodies found to protect hamsters against COVID-19

New research describes a novel route of prevention, using messenger ribonucleic acid (mRNA) molecules that encode protective antibodies within the recipient.

2 Nov 2022

Is there a difference in the risk of hospital admission between BA.1 and BA.2 cases treated with Sotrovimab?

Researchers compared the risk associated with hospitalization of sotrovimab-treated individuals infected with SARS-CoV-2 Omicron variants.

25 Oct 2022

Multiomics analysis identifies immunobiomarkers for COVID-19 severity in outpatients

In a recent study published in the journal eLife, researchers showed the utility of machine-learning models in identifying early immune signatures, which could reliably predict clinical and immunological outcomes in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected outpatients.

20 Oct 2022

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

30 Sep 2022

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products

Researchers comparatively evaluated antibody responses against SARS-CoV-2 among immunodeficient individuals pre- and post-intravenous immunoglobulin product infusions.

27 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

16 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

The current study focused on the ability of this nmAb to neutralize Delta, Omicron, and other VOCs, as well as its efficacy when given by the intranasal route in an animal model.

1 Sep 2022

SARS-CoV-2 nucleocapsid antigen levels and patient outcomes

In a new study, researchers assessed the correlation between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) antigen levels and hospitalized patient outcomes.

31 Aug 2022

Case report describes clinical manifestation of monkeypox, SARS-CoV-2, and HIV coinfection

Scientists have recently presented the first documented case of coinfection with monkeypox virus, SARS-CoV-2, and HIV.

23 Aug 2022

Study reveals safety and uptake of sotrovimab against severe SARS-CoV-2 infection in England

In a newly released study, researchers explored the sotrovimab uptake for severe COVID-19 prophylaxis and its safety across the community populations in England.

22 Aug 2022

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Researchers evaluated the neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 sub-variants by therapeutic monoclonal antibodies.

16 Aug 2022

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers reported mutations in SARS-CoV-2 Delta and Omicron variants of concern infection cases treated with neutralizing monoclonal antibodies.

20 Jul 2022

Sotrovimab News and Research

Evaluating dual direct-acting antivirals against persistent COVID-19

Nebulized mRNA-encoded antibodies found to protect hamsters against COVID-19

Is there a difference in the risk of hospital admission between BA.1 and BA.2 cases treated with Sotrovimab?

Multiomics analysis identifies immunobiomarkers for COVID-19 severity in outpatients

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products

Study reveals increased immunity evasion by Omicron BA.2.75.2

Antibody drugs are not recommended for patients with covid-19, say WHO experts

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

SARS-CoV-2 nucleocapsid antigen levels and patient outcomes

Case report describes clinical manifestation of monkeypox, SARS-CoV-2, and HIV coinfection

Study reveals safety and uptake of sotrovimab against severe SARS-CoV-2 infection in England

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

What are the hidden sources of SARS-CoV-2 evolution?

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

Efficacy of monoclonal antibodies against Omicron BA.1, BA.2, and BA.5

Why Omicron is more infectious than other SARS-CoV-2 variants

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News